TAMPA, FL, February 21, 2023 – EV Biologics Corp (OTC PINK:YECO), announced that it has successfully generated several mesenchymal stem/stromal cell (MSC) lines for secretome production and further cell line development. The cell banks were isolated from rigorously screened human donor tissue using xeno-free, serum-free culture media for isolation and expansion, after obtaining informed consent (from donors) for research and development. Analysis of the cell lines confirmed their identity as MSCs according to established criteria. [Read more…]
American Academy of Stem Cell Physicians To Hold Board Examination at Upcoming Annual Meeting
American Academy of Stem Cell Physicians offers Diplomat And Fellowship Certifications on June 2-4, 2023m in Miami, FL
MIAMI, February 26, 2023 – The Board of American Academy of Stem Cell Physicians is the official board certifying body of the American Academy of Stem Cell Physicians. (AASCP). As a nationally recognized academy with a mission to bring like-minded physicians together to increase awareness and education of regenerative medicine, the AASCP is proud to announce the Fellowship and Diplomat certification. [Read more…]
Heartseed and Novo Nordisk Dose First Patient with HS-001, an iPSC-Derived Cell Therapy to Treat Heart Failure
HS-001 consists of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs).
Clinical phase 1/2 study (LAPiS Study) will enroll 10 patients with advanced heart failure caused by ischaemic heart disease.
Tokyo, Japan and Bagsværd, Denmark, 10 February 2023 – Heartseed Inc. (Heartseed) and Novo Nordisk A/S today announced that Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated 4-week data on the patient, who lives with advanced heart failure and has given approval for the study to continue. [Read more…]
The European Innovation Council (EIC) awards the AcouSort project AcouSome SEK 26 million to develop groundbreaking technology for exosome-based diagnostics
August 13, 2022, Lund, Sweden – Exosomes are nanoparticles that enable human cells to communicate vital information with each other. They have potential to open a completely new field within diagnostics, as they can give us ‘status reports’ on organs such as the brain and heart, as well as give us vital information on tumor diseases, infectious diseases, pregnancy and stem cell conditions. EIC has announced that it granted AcouSort and its project partners SEK 26 million to develop an acoustofluidic thin-film actuated chip for exosome separation from blood. Of the SEK 26 million, SEK 12.2 million go directly to AcouSort, and the remainder of the funding is distributed to AcouSort’s partners Lund University, DTU, and Day One. The project will run for 36 months and is fully funded by the EU. [Read more…]
Pairing Cord Blood and Tissue Storage with Genetic Testing Services
One of the most prominent trends within the global cord blood banking industry is the pairing of cord blood and tissue storage with pre- and post-natal testing services, including genetic testing, genome sequencing, and metabolic screening services. The rise of this trend is driven by the ability of cord blood storage providers to offer complimentary services to existing clients, thereby expanding and diversifying their product portfolio.
As one cord blood executive recently told me, “They are looking to extend the relationship with the mother.” [Read more…]
- « Previous Page
- 1
- …
- 123
- 124
- 125
- 126
- 127
- …
- 334
- Next Page »